Skip to main content

Progestogens with Antiandrogenic Properties

Drugs volume 63, pages 463–492 (2003)Cite this article

Abstract

Chlormadinone acetate, cyproterone acetate and dienogest are potent, orally active progestogens, which have antiandrogenic instead of partial androgenic activity. They act mainly by blocking androgen receptors in target organs, but also reduce the activity of skin 5α-reductase, the enzyme responsible for converting testosterone to the more potent androgen, 5α-dihydrotestosterone, in sebaceous glands and hair follicles. Chlormadinone acetate and cyproterone acetate also suppress gonadotropin secretion, thereby reducing ovarian and adrenal androgen production.

Combined oral contraceptives (COCs) containing antiandrogenic progestogens provide highly effective contraception (gross and adjusted Pearl indices: 0–0.7 and 0–0.3, respectively) with excellent cycle control. Furthermore, COCs containing 2mg of chlormadinone acetate or cyproterone acetate plus 30 or 35μg of ethinylestradiol produced improvement or resolution of seborrhoea in 80% of users, acne in 59–70%, hirsutism in 36% and androgen-related alopecia in up to 86%.

These COCs are generally well tolerated, the main adverse effects being nonspecific or as expected for a COC (headache, breast tenderness and nausea). They have no clinically relevant effects on metabolic or liver functions or on body-weight. Effects on mood and libido are uncommon (<3.5% and <6% of women, respectively).

COCs containing antiandrogenic progestogens are likely to be particularly valuable in women with pre-existing androgen-related disorders who require contraception. They also increase the choice of products available for women with normal skin and hair who are concerned about the possibility of developing seborrhoea or acne with other COCs.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Table I
Table II
Fig. 3
Table III
Table IV
Table V
Table VI
Table VII
Fig. 4
Fig. 5

References

  1. Rabe T, Grunwald K, Runnebaum B. Hyperandrogenism in women. In: Runnebaum B, Rabe T, editors. Gynecological endocrinology and reproductive medicine. Vol. 1. Berlin, Heidelberg: Springer-Verlag, 1994

    Google Scholar 

  2. Diamanti-Kandarakis E, Tolis G, Duleba AJ. Androgens and therapeutic aspects of antiandrogens in women. J Soc Gynecol Investig 1995; 2(4): 577–92

    PubMed  CAS  Article  Google Scholar 

  3. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000; 21: 457–87

    PubMed  CAS  Article  Google Scholar 

  4. Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 1966; 45: 301–12

    PubMed  CAS  Article  Google Scholar 

  5. Bingham KDS. The metabolism of testosterone by human male scalp skin. J Endocrinol 1973; 57: 111–21

    PubMed  CAS  Article  Google Scholar 

  6. Wilson JD, Walker JD. The conversion of testosterone to 5α-androstan-17β-ol-3-one by skin slices in man. J Clin Invest 1969; 48: 37–9

    Google Scholar 

  7. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci U S A 1990; 87: 3640–4

    PubMed  CAS  Article  Google Scholar 

  8. Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 2001; 195: 138–46

    PubMed  CAS  Article  Google Scholar 

  9. Hughes IA. Minireview: sex differentiation. Endocrinology 2001; 142: 3281–7

    PubMed  CAS  Article  Google Scholar 

  10. Rittmaster RS. Clinical relevance of testosterone and dihydrotestosterone metabolism in women. Am J Med 1995; 98: 17–21S

    Article  Google Scholar 

  11. Davis S. Syndromes of hyperandrogenism in women. Aust Fam Physician 1999; 28(5): 47–51

    Google Scholar 

  12. Hopkinson ZEC, Sattar N, Fleming R, et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ 1998; 317: 329–32

    PubMed  CAS  Article  Google Scholar 

  13. Balen A. Pathogenesis of polycystic ovary syndrome: the enigma unravels? Lancet 1999; 354: 966–7

    PubMed  CAS  Article  Google Scholar 

  14. Anovulation and the polycystic ovary. In: Speroff L, Glass RH, Kase NG, editors. Clinical gynecologic endocrinology and infertility. 6th ed. Baltimore (MD): Lippincott Williams & Wilkins, 1999

  15. Acromite MT, Mantzoros CS, Leach RE, et al. Androgens in preeclampsia. Am J Obstet Gynecol 1999; 180: 60–3

    PubMed  CAS  Article  Google Scholar 

  16. Laivuori H, Kaaja R, Rutanen EM, et al. Evidence of high circulating testosterone in women with prior preeclampsia. J Clin Endocrinol Metab 1998; 83(2): 344–7

    PubMed  CAS  Article  Google Scholar 

  17. Sidelnikova VM, Orlova VG, Raisova AT, et al. Diagnosis of the causes and prevention of intrauterine fetal death in the second trimester of pregnancy in women with hyperandrogenism [in Russian]. Akush Ginekol (Mosk) 1991 Oct; (10): 16–9

  18. Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol 1994; 102(1): 1–32

    PubMed  CAS  Article  Google Scholar 

  19. Sansone G, Reisner RM. Differential rates of conversion of testosterone to dihydrotestosterone in acne and in normal human skin: possible pathogenetic factors in acne. J Invest Dermatol 1971; 56: 366–72

    PubMed  CAS  Article  Google Scholar 

  20. Abbou CC, Colombel M, International Anandron Study Group. Efficacy of nilutamide combined with castration on bone metastases of patients with previously untreated stage M+ prostate cancer: two prospective, randomized, placebo controlled studies. Joint Bone Spine 1998; 65: 528–9

    Google Scholar 

  21. Battmann T, Bonfils A, Branche C, et al. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J Steroid Biochem Mol Biol 1994; 48: 55–60

    PubMed  CAS  Article  Google Scholar 

  22. Matias JR, Gaillard M. Prevention of acne, hirsutism, and baldness in experimental animal models by the topical application of RU 58841, a pure non-steroidal androgen receptor inhibitor [abstract]. J Invest Dermatol 1995; 104: 577

    Google Scholar 

  23. Imamura K, Bonfils A, Diani A, et al. The effect of topical RU58841 (androgen receptor blocker) combined with minoxidil on hair growth in macaque androgenetic alopecia [abstract]. J Invest Dermatol 1998; 110: 679

    Google Scholar 

  24. Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14: 223–30

    PubMed  CAS  Article  Google Scholar 

  25. Diamanti-Kandarakis E. Current aspects of antiandrogen therapy in women. Curr Pharm Des 1999; 5: 707–23

    PubMed  CAS  Google Scholar 

  26. Hammerstein J, Moltz L, Schwartz U. Antiandrogens in the treatment of acne and hirsutism. J Steroid Biochem 1983; 19(1): 591–7

    PubMed  CAS  Article  Google Scholar 

  27. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf) 2002; 57: 231–4

    CAS  Article  Google Scholar 

  28. Venturoli S, Ravaioli B, Bagnoli A, et al. Contraceptive and therapeutic effectiveness of two low-dose ethinylestradiol and cyproterone acetate regimens in the treatment of hirsute patients. Eur J Contracept Reprod Health Care 1998; 3: 29–33

    PubMed  CAS  Article  Google Scholar 

  29. Committee on Safety of Drugs. Combined oral contraceptives: a statement by the committee on safety of drugs. BMJ 1970; 1: 231–2

    Article  Google Scholar 

  30. Bottiger LE, Boman G, Eklund G, et al. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; I(8178): 1097–101

    Article  Google Scholar 

  31. Neumann F, Duesterberg B, Laurent H. Development of progestogens. In: Runnebaum B, Rabe T, Kiesel L, editors. Female contraception. Berlin, Heidelberg: Springer-Verlag, 1988

    Google Scholar 

  32. Kuhl H. Chemie und Pharmakologie von Chlormadinonacetat. In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisierungserscheinungen. Stuttgart, New York: Schattauer, 1995: 1–12

    Google Scholar 

  33. Foster RH, Wilde MI. Dienogest. Drugs 1998; 56(5): 825–33

    PubMed  CAS  Article  Google Scholar 

  34. Oettel M, Graser T, Hoffmann H, et al. The preclinical and clinical profile of dienogest: a short overview. Med Actual/Drugs Today 1999; 35 Suppl C: 3–12

    CAS  Google Scholar 

  35. Oettel M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without a 17α-ethinyl group I: dienogest from a pharmacokinetic point of view. Med Actual/Drugs Today 1995; 31: 499–516

    CAS  Google Scholar 

  36. Juchem M, Scaffrath M, Pollow K, et al. Dienogest: Bindungsstudien an verschiedenen Rezeptor-und Serumproteinen. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagens. 2nd ed. Berlin: Walter de Gruyter, 1995: 119–33

    Google Scholar 

  37. Honma S, Iwamura S, Iizuka K, et al. Identification and anti-androgenic activity of the metabolites of 17α-acetoxy-6-chloropregna-4,6,-diene-,3,20-dione (chlormadinone acetate) in the rat, rabbit, dog and man. Chem Pharm Bull (Tokyo) 1977; 25: 2019–31

    CAS  Article  Google Scholar 

  38. Kuhl H, Jung-Hoffmann C. Pharmakologie der Gestagene. In: Kuhl H, Jung-Hoffmann C, editors. Kontrazeption. Stuttgart: Thieme, 1999: 28–31

    Google Scholar 

  39. Tindall D, French J, Nayfeh FS. Estradiol-17β inhibition of androgen uptake, metabolism and binding in epididymis of adult male rats in vivo: a comparison with cyproterone acetate. Steroids 1981; 37: 257–68

    PubMed  CAS  Article  Google Scholar 

  40. Brennan DM, Kraay RJ. Chlormadinone acetate; a new highly active gestation-supporting agent. Acta Endocrinol (Copenh) 1963; 44: 367–79

    CAS  Google Scholar 

  41. Oettel M, Carol W, Elger W, et al. A 19-norprogestin without a 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Med Actual/Drugs Today 1995; 31: 517–36

    CAS  Google Scholar 

  42. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171–97

    PubMed  CAS  Article  Google Scholar 

  43. Neumann F. The physiological action of progesterone and the pharmacological effects of progestogens: a short review. Postgrad Med J 1978; 54 Suppl. 2: 11–24

    PubMed  CAS  Google Scholar 

  44. Kincl FA, Dorfman RI. Anti-ovulatory activity of subcutaneously injected steroids in the adult oestrus rabbit. Acta Endocrinol Suppl (Copenh) 1963; 73: 3–15

    CAS  Google Scholar 

  45. Moore C, Luderschmidt C, Moltz L, et al. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®. Med Actual/Drugs Today 1999; 35 Suppl C: 69–78

    CAS  Google Scholar 

  46. Dahl E, Hars R. The ultrastructure of the accessory sex organs of the male rat. Acta Endocrinol (Copenh) 1975; 80: 199–208

    CAS  Google Scholar 

  47. Honma S, Ugi S, Iizuka K, et al. The effects of anti-androgenic agents on metabolism and biosynthesis of testosterone: I. Testosterone metabolic regulation in the liver and the biosynthesis in the testes of rats treated with chlormadinone acetate [in Japanese]. Folia Endocrinol Jpn 1977; 53: 703–18

    CAS  Google Scholar 

  48. Lax ER, Baumann F, Schriefers H. Changes in the activities of microsomal enzymes involved in hepatic steroid metabolism in the rat after administration of androgenic, estrogenic, progestational, anabolic and catatonic steroids. Biochem Pharmacol 1984; 33: 1235–41

    PubMed  CAS  Article  Google Scholar 

  49. Schürenkämper P, Lisse K. Die Metabolisierung von 4-14-C-Pregnenolon in Gewebschnitten menschlicher Ovarien und deren Beeinflussung durch Chlormadinonacetat. Endokrinologie 1975; 66: 135–44

    PubMed  Google Scholar 

  50. Neumann F, Elger W. The effect of a new antiandrogenic steroid, 6-chloro-17-hydroxyl-1α.2α-methyl-enepregna-4.6-diene-3.20-dione acetate (cyproterone acetate) on the sebaceous glands of mice. J Invest Dermatol 1966; 46: 561–72

    CAS  Google Scholar 

  51. Ebling FJ. Factors influencing the response of the sebaceous glands of the rat to androgen. Br J Dermatol 1970; 82: 9–14

    Article  Google Scholar 

  52. Stötzner W, Kurischko A, Freund R, et al. Tierexperimentell-endokrinologische Charakterisierung des Gestagenes Dienogest (STS 557) II. Antigonadotrope, gestagene, androgene und antiandrogene Wirkungen. In: Stech D, Carol W (Hrsg) III, editors. Jenaer Symposium zur hormonalen Kontrazeption 1984. Jena: Friedrich-Schiller-Universität, 1985: 165–82

    Google Scholar 

  53. Belara® Product Monograph 1st ed. Grünenthal GmbH, 2001 Aug

  54. Hümpel M, Wendt H, Schulze P-E, et al. Bioavailability and pharmacokinetics of cyproterone actate after oral administration of 2.0mg cyproterone acetate in combination with 50 μg ethinyloestradiol to 6 young women. Contraception 1977; 15(5): 579–88

    PubMed  Article  Google Scholar 

  55. Hümpel M, Nieuweboer B, Wendt H, et al. Investigations of pharmacokinetics of ethinylestradiol to specific consideration of possible first-pass effect in women. Contraception 1979; 19: 421–32

    PubMed  Article  Google Scholar 

  56. Speck U, Wendt H, Schulze P-E, et al. Bioavailability and pharmacokinetics of cyproterone acetate-14C and ethinylo-estradiol-3H after oral administration as a coated tablet (SH B 209 AB). Contraception 1976; 14: 151–63

    PubMed  CAS  Article  Google Scholar 

  57. Hobe G, Hillesheim HG, Küntzel B, et al. Studies on non-protein bound dienogest in plasma of different species [abstract]. Naunyn Schmiedebergs Arch Pharmacol Suppl 1993; 347: R44

  58. Gallegos AJ, Gonzales-Diddi M, Merino M, et al. Tissue localisation of radioactive chlormadinone acetate and progesterone in the human. Contraception 1970; 1: 151–61

    Article  Google Scholar 

  59. Schubert K, Hobe G, Kaufmann G, et al. Synthesis, effects, and metabolism of the progestogen and potential interceptive dienogest. Presented at the International Symposium on the Chemistry of Natural Products; 1984 Jul 9–14; Poznan, Poland. In: Zalewski RI, Skolik JJ, editors. Natural products chemistry. Amsterdam: Elsevier Science Publishers, 1985: 143–58

    Google Scholar 

  60. Hobe G, Hillesheim HG, Schumann W, et al. Studies on pharmacokinetics of STS 557 in animal species and man. Exp Clin Endocrinol 1983; 81: 158–67

    PubMed  CAS  Article  Google Scholar 

  61. Forchielli E, Murthy DVK. Metabolism of chlormadinone acetate in the human and laboratory animals: report from Syntex Research Center, Syntex Corporation, Palo Alto, California, 1973 Jun 14

  62. Dorfman R. Chlormadinone acetate: some pharmacological, toxicological and pharmacokinetic aspects in various species. In: Kewitz H, editor. Nebenwirkungen Contrazeptiver Steroide Symposium 1970. Berlin: Westkreuz Verlag, 1971: 139–44

    Google Scholar 

  63. Forchielli E. Distribution, metabolism and elimination of rs-1280 after intravenous administration to dogs. Report from Syntex International ATSA, 1970 Feb 25

  64. Hanasono GK, Fischer LJ. The excretion of tritium-labelled chlormadinone acetate, mestranol, norethindrone and norethynodrel in rats and the enterohepatic circulation of metabolites. Drug Metab Dispos 1974; 2: 159–68

    PubMed  CAS  Google Scholar 

  65. Carol W, Klinger G, Michels W, et al. Studies on the pharmacokinetics of contraceptive steroids under steady-state conditions [in German]. Zentralb Gynakol 1991; 113: 1298–303

    CAS  Google Scholar 

  66. Rudolf K, Kunkel S, Rudolf H, et al. Der Einfluss von Mestranol und Chlormadinonacetat auf TSH, T4, TBC und TF4-Index beim Turner Syndrom. Zentralb Gynakol 1986; 108: 551–9

    CAS  Google Scholar 

  67. Lobl TJ. Androgen transport proteins: physical properties, hormonal regulation, and possible mechanism of T, CBG and ABP action. Arch Androl 1981; 7: 133–51

    PubMed  CAS  Article  Google Scholar 

  68. Anderson DC. Sex hormone binding globulin. Clin Endocrinol 1974; 3: 69–96

    CAS  Article  Google Scholar 

  69. Makhzangy MN, Wynn V, Lawrence DM. Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin Endocrinol 1979; 10: 39–45

    Article  Google Scholar 

  70. Ebling FJ. Hormonal control and methods of measuring sebaceous gland activity. J Invest Dermatol 1974; 62: 161–71

    PubMed  CAS  Article  Google Scholar 

  71. van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990; 41(4): 345–52

    PubMed  CAS  Article  Google Scholar 

  72. Mowszowicz I, Wright F, Vincens M, et al. Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem 1984; 20: 757–61

    PubMed  CAS  Article  Google Scholar 

  73. Handy RW, Hess TR, Wall ME. Comparative metabolism of chlormadinone acetate [abstract]. The Pharmacologist 1973; 15: 228

    Google Scholar 

  74. Wiechert R, Neumann F. Gestagene Wirksamkeit von 1-Methyl-und 1.2α-Methylen-Steroiden. Arzneimittel Forschung 1965; 15: 3–16

    Google Scholar 

  75. Kuhl H. Comparative pharmacology of newer progestins. Drugs 1996; 51: 188–215

    PubMed  CAS  Article  Google Scholar 

  76. Taubert HD, Kuhl H. Kontrazeption mit Hormonen. Stuttgart: Thieme, 1995

    Google Scholar 

  77. Rudel HW, Lebherz T, Maqueo-Topete M, et al. Assay of the anti-oestrogenic effects of progestogens in women. J Reprod Fertil 1967; 13: 199–203

    PubMed  CAS  Article  Google Scholar 

  78. Rudel HW. Antifertility effects of low dose progestin. Fed Proc 1970; 29(3): 1228–31

    PubMed  CAS  Google Scholar 

  79. Mears E, Vessey MP, Andolsek L, et al. Preliminary evaluation of four oral contraceptives containing only progestogens. BMJ 1969; 2: 730–4

    PubMed  CAS  Article  Google Scholar 

  80. Kühne D, Seidl ST, Göretzlehner G. Contraceptive treatment with chlormadinone and its effect on the endometrium: a histological investigation. Endokrinologie 1972; 59(3): 295–306

    PubMed  Google Scholar 

  81. Kühne D, Göretzlehner G, Seidl ST. Contraception with low dose chlormadinone acetate: clinical and histological results. Acta Eur Fertil 1970; 2: 75–84

    PubMed  Google Scholar 

  82. Rudel HW, Kincl FA. Biology of anti-fertility steroids. Acta Endocrinol (Copenh) 1966; 51 Suppl. 105: 1–45

    Google Scholar 

  83. Martinez-Manautou J, Giner-Velasquez J, Cortes-Gallegos V, et al. Daily progestogen for contraception: a clinical study. BMJ 1967; 2: 730–2

    PubMed  CAS  Article  Google Scholar 

  84. Larsson-Cohn U. Contraceptive treatment with low doses of gestagens. Acta Endocrinol Suppl (Copenh) 1970; 144 Suppl. 144: 7–46

    Google Scholar 

  85. Shahani SM, Munsif MK. Clinical trial with continuous low dosage (0.5 mg) chlormadinone acetate. J Biosoc Sci 1972; 4: 1–8

    PubMed  CAS  Article  Google Scholar 

  86. Di Carlo F, Gallo E, Conti G, et al. Changes in the binding of oestradiol to uterine oestrogen receptors induced by some progesterone and 19-nor-testosterone derivatives. J Endocrinol 1983; 98: 385–9

    PubMed  Article  Google Scholar 

  87. Kreitmann B, Bugat R, Bayard F. Estrogen and progestin regulation of the progesterone receptor concentration in human endometrium. J Clin Endocrinol Metab 1979; 49: 926–9

    PubMed  CAS  Article  Google Scholar 

  88. Cheng CV, Boettcher B. Effects of steroids on the in vitro forward migration of human spermatozoa. Contraception 1981; 24: 183–94

    PubMed  CAS  Article  Google Scholar 

  89. Gregoire AT, Ustay K. Effect of chlormadinone on human cervical mucus and its glycogen content. Fertil Steril 1969; 20: 938–43

    PubMed  CAS  Google Scholar 

  90. Martinez-Manautou J, Cortez V, Giner J, et al. Low doses of progestogen as an approach to fertility control. Fertil Steril 1966; 17: 49–57

    PubMed  CAS  Google Scholar 

  91. Martinez-Manautou J, Giner-Velasquez J, Rudel H. Continuous progestogen contraception: a dose relationship study with chlormadinone acetate. Fertil Steril 1967; 18(1): 57–62

    PubMed  CAS  Google Scholar 

  92. MacDonald RR, Lumley IB, Coulson A, et al. Chlormadinone acetate as an oral contraceptive: clincal results and the incidence of ovulation. J Obstet Gynaecol Br Commonw 1968; 75: 1123–7

    PubMed  CAS  Article  Google Scholar 

  93. Erb H. Zur Wirkung niedrig dosierter Progestagene auf die Motilität der menschlichen Tube. Geburtsh Frauenheilk 1969; 29: 255–60

    PubMed  CAS  Google Scholar 

  94. Moore C, Walter F, Klinger G, et al. The influence of dienogest on ovulation in younger women and on chosen endocrinological parameters [in German]. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagenes. 2nd ed. Berlin: Walter de Gruyter, 1995: 161–9

    Google Scholar 

  95. Graham S, Fraser IS. The progestogen-only minipill. Contraception 1982; 26: 373–88

    PubMed  CAS  Article  Google Scholar 

  96. Johansson EDB. Luteolytic effect of gestagens [letter]. Acta Obstet Gynecol Scand 1971; 50: 75

    Google Scholar 

  97. Larsson-Cohn U, Johansson EDB, Wide L, et al. Effects of continuous daily administration of 0.5mg of chlormadinone acetate on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens. Acta Endocrinol (Copenh) 1970; 63: 705–16

    CAS  Google Scholar 

  98. Kuhl H, Jung-Hoffmann C, Storch A, et al. New aspects on the mechanism of action of contraceptive steroids: recent pharmacokinetic studies of low dose formulations. Adv Contracept 1991; Suppl. 3: 149–63

  99. Oettel M, Carol W, Gräser T, et al. Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations [in German]. Zentralb Gynakol 1997; 119(12): 597–606

    CAS  Google Scholar 

  100. Schleussner E, Michels W, Bethge S, et al. Die Wirkung von Dienogest auf die hypothalamisch-hypophysäre Achse: Ergebnisse einer Pilotstudie. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagenes. 2nd ed. Berlin: Walter de Gruyter, 1995: 171–9

    Google Scholar 

  101. Gräser T, Oettel M. Organ targeting with the oral progestin dienogest. Drugs Today 1996; 32 Suppl H: 43–55

    Google Scholar 

  102. Erdmann D, Schindler E-M, Schindler AE. Die ovarielle Suppression unter Diane 35/50®. Geburtshilfe Frauenheilkd 1994; 54: 627–33

    PubMed  CAS  Article  Google Scholar 

  103. Spona J, Feichtinger W, Kindermann C, et al. Modulation of ovarian function by an oral contraceptive containing 30 μg of ethinyl estradiol in combination with 2.00mg dienogest. Contraception 1997; 56: 185–91

    PubMed  CAS  Article  Google Scholar 

  104. Hirvonen E, Stenman U-H, Mälkönen M, et al. New natural oestradiol/cyproterone acetate oral contraceptive for premenopausal women. Maturitas 1988; 10: 201–13

    PubMed  CAS  Article  Google Scholar 

  105. Hirvonen E, Allonen H, Anttila M, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas 1995; 21: 27–32

    PubMed  CAS  Article  Google Scholar 

  106. Hoffmann H, Moore C, Kovacs L, et al. Alternatives for the replacement of ethinylestradiol by natural 17β-estradiol in dienogest-containing oral contraceptives. Drugs Today 1999; 35 Suppl C: 105–13

    CAS  Google Scholar 

  107. Recio R, Hernández-Morales C, Pérez-Rodríguez RM, et al. Effects of low steroid doses administered in the mid and late follicular phase on the LH surge, ovarian steroids and follicular maturation in eumenorrheic women. Adv Contracept 1997; 13: 39–46

    PubMed  CAS  Article  Google Scholar 

  108. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03mg (Belara): results of a post-marketing surveillance study. Clin Drug Invest 2002; 22(4): 221–31

    CAS  Article  Google Scholar 

  109. Zahradnik HP, Goldberg J, Andreas J-O. Efficacy and safety of the new antiandrogenic oral contraceptive Belara®. Contraception 1998; 57: 103–9

    PubMed  CAS  Article  Google Scholar 

  110. Göretzlehner G. Sicherheit, Verträglichkeit und Nutzen von Chlormadinonacetat-Östrogen-Produkten. In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisie-rungserscheinungen. New York, Stuttgart: Schattauer, 1995: 111–27

    Google Scholar 

  111. Audebert A, Emperaire JC, Gauthier A, et al. Étude clinique multicentrique d’une association de 35 μg d’éthinylestradiol et de 2mg d’acétate de cyprotérone. Rev Fr Gynecol Obstet 1991; 86: 697–9

    PubMed  CAS  Google Scholar 

  112. Fugère P, Percival-Smith RKL, Lussier-Cacan S, et al. Cyproterone acetate/ethinyl estradiol in the treatment of acne: a comparative dose-response study of the estrogen component. Contraception 1990; 42(2): 225–34

    PubMed  Article  Google Scholar 

  113. Moore C, Feichtinger W, Klinger G, et al. Clinical findings with the dienogest-containing oral contraceptive Valette®. Drugs Today 1999; 35 Suppl C: 53–68

    CAS  Google Scholar 

  114. Zimmermann T, Dietrich H, Wisser K-H, et al. Efficacy and tolerability of the dienogest-containing oral contraceptive Valette®: results of a postmarketing surveillance study. Drugs Today 1999; 35 Suppl C: 79–87

    CAS  Google Scholar 

  115. Jeppsson S, Kullander S. Experience with chlormadinone acetate in continuous low dose as an oral contraceptive. Fertil Steril 1970; 21(4): 307–13

    PubMed  CAS  Google Scholar 

  116. Runnebaum B, Rabe T. Gynäkologische Endokrinologie. Berlin: Springer-Verlag, 1994: 413

    Google Scholar 

  117. Llewellyn-Jones D, editor. Fundamentals of obstetrics and gynaecology. Vol 2. Gynaecology. 5th ed. London: Faber and Faber Ltd, 1990

    Google Scholar 

  118. Breckwoldt M, Wieacker P. Hirsutismus. In: Bettendorf G, Breckwoldt M, editors. Reproduktionsmedizin. Stuttgart: Fischer, 1989: 483–7

    Google Scholar 

  119. Breckwoldt M, Zahradnik HP, Wieacker P. Hirsutism. In: Orfanos CE, Happle R, editors. Hair and hair diseases. Berlin: Springer-Verlag, 1990: 777–89

    Chapter  Google Scholar 

  120. Ebling FJ. Hormonal control of sebaceous glands in experimental animals. In: Montagna W, Ellis RA, Silver AF, editors. Advances in the biology of skin. Vol 4. The sebacious gland. Oxford: Pergamon Press, 1963: 200–19

    Google Scholar 

  121. McKenna TJ. The use of anti-androgens in the treatment of hirsutism. Clin Endocrinol (Oxf) 1991; 35: 1–3

    CAS  Article  Google Scholar 

  122. Dieben T, Vromans L, Theeuwes C, et al. The effects of CRT-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994; 50: 373–82

    PubMed  CAS  Article  Google Scholar 

  123. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinylestradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997; 89(4): 615–22

    PubMed  CAS  Article  Google Scholar 

  124. Gollnick H, Wünsch C. The effects of an oral contraceptive containing cyproterone-acetate on acne, seborrhea and hirsutism: results of an open-label multicenter study in 890 women [abstract]. Australas J Dermatol 1997; 38 Suppl. 2: 261

    Google Scholar 

  125. Erkkola R, Hirvonen E, Luikku J, et al. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 1990; 69: 61–5

    PubMed  CAS  Article  Google Scholar 

  126. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud 1996; 41(4): 423–9

    PubMed  CAS  Google Scholar 

  127. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinylestradiol in the treatment of acne. Acta Obstet Gynecol Scand 1986; 134: 29–32

    CAS  Article  Google Scholar 

  128. Worret I, Arp W, Zahradnik H-P. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara®) and EE/LNG (Microgynon®). Dermatology 2001; 203: 38–44

    PubMed  CAS  Article  Google Scholar 

  129. Grundy SM. Cholesterol and coronary heart disease: a new era. JAMA 1986; 256: 2849–58

    PubMed  CAS  Article  Google Scholar 

  130. Heikki Frick M. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45

    Article  Google Scholar 

  131. Krauss RM. Effects of progestational agents on serum lipids and lipoproteins. J Reprod Med 1982; 27: 503–10

    PubMed  CAS  Google Scholar 

  132. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–81

    PubMed  CAS  Article  Google Scholar 

  133. Porkka KVK, Erkkola R, Taimela S, et al. Influence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors. Ann Med 1995; 27: 193–8

    PubMed  CAS  Article  Google Scholar 

  134. Anderson KK, Kappas A. Hormones and liver function. In: Schiff L, Schiff ER, editors. Diseases of the liver. Philadelphia (PA): JB Lippincott Co, 1982: 167–235

    Google Scholar 

  135. Meade TW, Haines AP. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50μg or 30μg oestrogen. Lancet 1977; 2(8045): 948–51

    PubMed  CAS  Article  Google Scholar 

  136. Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988; 158: 1646–52

    PubMed  CAS  Google Scholar 

  137. Sabra A, Bonnar J. Hemostatic system changes induced by 50μg and 30μg estrogen/progestogen oral contraceptives. J Reprod Med 1983; 28: 85–91

    PubMed  CAS  Google Scholar 

  138. Beck P. Alterations of lipid metabolism by contraceptive steroids. J Steroid Biochem 1975; 6: 957–9

    PubMed  CAS  Article  Google Scholar 

  139. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ 1993; 306: 956–63

    PubMed  CAS  Article  Google Scholar 

  140. Mishell Jr DR. Oral contraception: past, present and future perspectives. Int J Fertil 1991; 36: 7–18

    PubMed  Google Scholar 

  141. Miccoli R, Orlandi MC, Fruzzetti F, et al. Metabolic effects of three new low-dose pills: a six-month experience. Contraception 1989; 39(6): 643–52

    PubMed  CAS  Article  Google Scholar 

  142. Winkler UH. Chlormadinonacetate: Stoffwechsel und Hämostase. In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisierungserscheinungen. Stuttgart, New York: Schattauer, 1995: 1–12

    Google Scholar 

  143. Winkler UH, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30μg ethinylestradiol and either 2mg chlormadinone acetate or 150μg desogestrel. Eur J Contracept Reprod Health Care 1999; 4: 145–54

    PubMed  CAS  Google Scholar 

  144. Spona J, Feichtinger W, Kindermann C, et al. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30μg ethinyl estradiol and 2.00mg dienogest on the hemostatic system. Contraception 1997; 56: 67–75

    PubMed  CAS  Article  Google Scholar 

  145. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427–9

    PubMed  CAS  Article  Google Scholar 

  146. Gompel A, Carpentier S, Frances C, et al. Risk of venous thromboembolism and oral contraceptives [letter]. Lancet 2002; 359: 1348

    PubMed  CAS  Article  Google Scholar 

  147. World Health Organization. Collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1995; 346: 1575–82

    Google Scholar 

  148. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93

    PubMed  CAS  Article  Google Scholar 

  149. Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83–8

    PubMed  CAS  Article  Google Scholar 

  150. Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low-dose estrogen oral contraceptives. J Obstet Gynecol 1995; 15: 195–200

    Article  Google Scholar 

  151. Farmer RDT, Lawrenson RA, Thompson GR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83–8

    PubMed  CAS  Article  Google Scholar 

  152. Scheen AJ, Jandrain BJ, Humblet DMP, et al. Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism. Fertil Steril 1993; 59(4): 797–802

    PubMed  CAS  Google Scholar 

  153. Aznar R, Lara R, Zarco D, et al. The effect of various contraceptive hormonal therapies in women with normal and diabetic oral glucose tolerance test. Contraception 1976; 13(3): 299–311

    PubMed  CAS  Article  Google Scholar 

  154. Jandrain BJ, Humblet DMP, Jaminet CB, et al. Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: a one-year randomized, prospective, comparative trial. Am J Obstet Gynecol 1990; 163: 378–81

    PubMed  CAS  Google Scholar 

  155. Köhler G, Lembke S, Brachmann K, et al. Routine liver function testing during treatment of endometriosis with the progestin dienogest [in German]. Zentralb Gynakol 1989; 111: 807–10

    Google Scholar 

  156. Baum JK, Holtz F, Bookstein JJ, et al. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 2(7835): 926–9

    PubMed  CAS  Article  Google Scholar 

  157. Rabe T, Feldmann K, Grunwald K, et al. Liver tumours and steroid hormones in women. Gynecol Endocrinol 1995; 9 Suppl. 3: 1–81

    Google Scholar 

  158. Rabe T, Feldmann K, Heinemann L, et al. Cyproterone acetate. Is it hepato-or genotoxic? Drug Saf 1996; 14: 25–38

    CAS  Google Scholar 

  159. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991; 51: 5023–44

    Google Scholar 

  160. ECETOC. DNA and protein adducts: evaluation of their use in exposure monitoring and risk assessment. Brussels: ECETOC, ECETOC Monograph No 13, 1989

  161. Purchase IFH. Current knowledge of mechanisms of carcino-genicity: genotoxicity versus non-genotoxins. Hum Exp Toxicol 1994; 13: 17–28

    PubMed  CAS  Article  Google Scholar 

  162. Fahrig R. General strategy for the assessment of genotoxicity. Mutat Res 1991; 252: 161–3

    PubMed  CAS  Article  Google Scholar 

  163. Matthiesen T, Wöhrmann T. Chlormadinonacetat: Aspekte zur Toxikologie. In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisierungserscheinungen. New York, Stuttgart: Schattauer, 1995: 29–36

    Google Scholar 

  164. Heinemann LAJ, Will-Shahab L. Active surveillance study on patients treated with CPA long-term: the SEHOST project. Berlin: Research Report ZEG, 1995 Jun 20

    Google Scholar 

  165. Beck P, Malarkey WB. Serum prolactin concentration in women treated with chlormadinone acetate. Am J Obstet Gynecol 1976; 124(6): 578–81

    PubMed  CAS  Google Scholar 

  166. Testa G, Vegetti W, Motta T, et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 1998; 58: 69–73

    PubMed  CAS  Article  Google Scholar 

  167. Back DJ, Houlgrave R, Tna JF, et al. Effect of progestogens, gestodene, 3-ketodesogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol 1991; 38: 219–25

    PubMed  CAS  Article  Google Scholar 

  168. Guengerich FP. Inhibition of oral contraceptive steroid metabolizing enzymes by steroids and drugs. Am J Obstet Gynecol 1990; 163: 2159–63

    PubMed  CAS  Google Scholar 

  169. Böcker R, Kleingeist B, Eichorn M, et al. In vitro interaction of contraceptive steroids with human liver cytochrome P-450 enzymes. Adv Contracept 1991; 3 Suppl. 3: 140–8

    Google Scholar 

  170. Böcker R, Kleingeist B. Der Einfluss von Dienogest auf das humane Cytochrom P450-Enzymsystem in vitro. In: Teichmann AT, editor. Dienogest: Präklinik und Klinik eines Gestagenes. 2nd ed. Berlin: Walter de Gruyter, 1995: 141–7

    Google Scholar 

  171. Balogh A, Liewald T, Liewald S, et al. The influence of a new sexual steroid-dienogest-on the metabolism of caffeine and meptazimol [in German]. Zentralb Gynakol 1990; 112(12): 735–46

    CAS  Google Scholar 

  172. Balogh A, Gessinger S, Svarovsky U, et al. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pyridine metabolite in humans? Eur J Clin Pharmacol 1998; 54: 729–34

    PubMed  CAS  Article  Google Scholar 

  173. Kuhnz W, Löfberg B. Urinary excretion of 6β-hydroxycortisol in women during treatment with different oral contraceptive formulations. J Steroid Biochem Mol Biol 1995; 55(1): 129–33

    PubMed  CAS  Article  Google Scholar 

  174. Goldzieher JW, Moses LE, Averkin E, et al. Nervousness and depression attributed to oral contraceptives: a double-blind, placebo-controlled study. Am J Obstet Gynecol 1971; 111(8): 1013-20

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review/study.

Author information

Authors and Affiliations

  1. Hôtel Dieu, Lyon, France

    Daniel Raudrant

  2. Universitätsklinikum Frauenklinik, Heidelberg, Germany

    Thomas Rabe

Authors
  1. Daniel Raudrant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Rabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Rabe.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Raudrant, D., Rabe, T. Progestogens with Antiandrogenic Properties. Drugs 63, 463–492 (2003). https://doi.org/10.2165/00003495-200363050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363050-00003

Keywords

  • Androgen Receptor
  • Acne
  • Ethinylestradiol
  • Cyproterone Acetate
  • Dienogest